Postmenopausal: Clinical Trials

4 trials for Postmenopausal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 withdrawn. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Completed 2, Recruiting 1, Withdrawn 1

Follow Postmenopausal: new trials by email Literature Review of Postmenopausal trials Research Report on Postmenopausal

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cyclic vs. Constant Estradiol: Regimens' Effects on Brain Health
Cyclic Estradiol, Continuous Estradiol - Menopause, Healthy Adult
Phase 4RecruitingUniversity of Colorado, Denver402026-07-152026-09-21
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Anastrozole, Exemestane, Laboratory Biomarker Analysis - HER2/Neu Negative, Invasive Breast Carcinoma
Phase 4WithdrawnFred Hutchinson Cancer Center2018-09-012018-12-27
Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route
oestradiol - Postmenopausal
Phase 4CompletedUniversity Hospital, Toulouse402006-09-012017-05-11
Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women
progesterone - Healthy, Postmenopausal
Phase 4CompletedMax-Planck-Institute of Psychiatry102003-11-012007-09-17

Narrower conditions

Breast Carcinoma In Situ (1)  ·  Breast Neoplasms (1)

Broader conditions

Breast Diseases (1)  ·  Carcinoma (1)  ·  Carcinoma in Situ (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

Anastrozole (1)  ·  Estradiol (1)  ·  Letrozole (1)  ·  Ortho Evra (1)  ·  Progesterone (1)  ·  Tamoxifen (1)  ·  Toremifene (1)  ·  estradiol, estriol drug combination (1)  ·  exemestane (1)

Sponsors

Fred Hutchinson Cancer Center (1)  ·  Max-Planck-Institute of Psychiatry (1)  ·  University Hospital, Toulouse (1)  ·  University of Colorado, Denver (1)

Countries

United States (2)  ·  France (1)  ·  Germany (1)

Top investigators

Axel Steiger, Prof., MD (1)  ·  Neill Epperson, MD (1)  ·  Vijayakrishna Gadi (1)

Results publications

PMID 22096248

NIH funding

P30CA015704 (1)